Human disease
gastrointestinal stromal tumor
Mondo defines it as: “Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal (GI) tract, typically presenting in adults over the age of 40 (mean age 63), and only rarely in children, in various regions of the GI tract, most commonly the stomach or small intestine but also less commonly in the esophagus, appendix, rectum and colon. GISTs can be asymptomatic or present with various non-specific signs, depending on the location and size of tumor, such as loss of appetite, anemia, weight loss, fatigue, abdominal discomfort or fullness, nausea, vomiting, as well as an abdominal mass, blood in stool, and intestinal obstruction. GISTs can also be seen in familial syndromes such as Carney triad and neurofibromatosis type 1.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1516 | Gastrointestinal stromal tumour | OMIA's OMIM numbers | 1 | Drug |
85.2
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| KIT | 0.89 | 7,740 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Avapritinib | KIT | Approved |
| Imatinib | KIT | Approved |
| Ripretinib | KIT | Approved |
| Sunitinib | KIT | Approved |
| Tas-116 | None of these genes | Approved |
| Bevacizumab | None of these genes | Phase 3 |
| Bezuclastinib | None of these genes | Phase 3 |
| Crenolanib | None of these genes | Phase 3 |
| Famitinib | KIT | Phase 3 |
| Idrx-42 | None of these genes | Phase 3 |
| Masitinib | KIT | Phase 3 |
| Nilotinib | None of these genes | Phase 3 |
| Olverembatinib | None of these genes | Phase 3 |
| Regorafenib | KIT | Phase 3 |
| Retaspimycin | None of these genes | Phase 3 |
| Amcasertib | None of these genes | Phase 2 |
| Atezolizumab | None of these genes | Phase 2 |
| Avelumab | None of these genes | Phase 2 |
| Axitinib | None of these genes | Phase 2 |
| Biib021 | None of these genes | Phase 2 |
| Brostallicin | None of these genes | Phase 2 |
| Cabozantinib | None of these genes | Phase 2 |
| Catequentinib | KIT | Phase 2 |
| Cediranib | KIT | Phase 2 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 2 |
| Dabrafenib | None of these genes | Phase 2 |
| Dasatinib Anhydrous | KIT | Phase 2 |
| Docetaxel Anhydrous | None of these genes | Phase 2 |
| Dovitinib | KIT | Phase 2 |
| Envafolimab | None of these genes | Phase 2 |
| Epacadostat | None of these genes | Phase 2 |
| Ganetespib | None of these genes | Phase 2 |
| Gemcitabine | None of these genes | Phase 2 |
| Guadecitabine | None of these genes | Phase 2 |
| Ipilimumab | None of these genes | Phase 2 |
| Lenvatinib | None of these genes | Phase 2 |
| Linsitinib | None of these genes | Phase 2 |
| Luminespib | None of these genes | Phase 2 |
| Motesanib | KIT | Phase 2 |
| Nivolumab | None of these genes | Phase 2 |
| Oblimersen Sodium | None of these genes | Phase 2 |
| Olaratumab | None of these genes | Phase 2 |
| Onalespib | None of these genes | Phase 2 |
| Paclitaxel | None of these genes | Phase 2 |
| Palbociclib | None of these genes | Phase 2 |
| Pazopanib | KIT | Phase 2 |
| Peginterferon Alfa-2b | None of these genes | Phase 2 |
| Pembrolizumab | None of these genes | Phase 2 |
| Pemigatinib | None of these genes | Phase 2 |
| Perifosine | None of these genes | Phase 2 |
| Ponatinib | None of these genes | Phase 2 |
| Rivoceranib | None of these genes | Phase 2 |
| Rogaratinib | None of these genes | Phase 2 |
| Selumetinib | None of these genes | Phase 2 |
| Sorafenib | KIT | Phase 2 |
| Temozolomide | None of these genes | Phase 2 |
| Temsirolimus | None of these genes | Phase 2 |
| Trametinib | None of these genes | Phase 2 |
| Vandetanib | None of these genes | Phase 2 |
| Vatalanib | KIT | Phase 2 |
| Vemurafenib | None of these genes | Phase 2 |
| Xl-820 | KIT | Phase 2 |
| Binimetinib | None of these genes | Phase 1/2 |
| Everolimus | None of these genes | Phase 1/2 |
| Infigratinib | None of these genes | Phase 1/2 |
| Pexidartinib | KIT | Phase 1/2 |
| Selinexor | None of these genes | Phase 1/2 |
| Spartalizumab | None of these genes | Phase 1/2 |
| Alpelisib | None of these genes | Phase 1 |
| Buparlisib | None of these genes | Phase 1 |
| Cetuximab | None of these genes | Phase 1 |
| Dalfampridine | None of these genes | Phase 1 |
| Evofosfamide | None of these genes | Phase 1 |
| Fluorouracil | None of these genes | Phase 1 |
| Folinic Acid | None of these genes | Phase 1 |
| Larotrectinib | None of these genes | Phase 1 |
| Midazolam | None of these genes | Phase 1 |
| Oxaliplatin | None of these genes | Phase 1 |
| Sirolimus | None of these genes | Phase 1 |
| Tidutamab | None of these genes | Phase 1 |
| Umbralisib | None of these genes | Phase 1 |
| Ziftomenib | None of these genes | Phase 1 |
| Entacapone | None of these genes | Early phase 1 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.